

From: Petrik, Amy (NIH/NIAID) [E]
Sent: Thu, 12 Dec 2019 13:06:45 +0000
To: Stein, Judy (NIH/VRC) [C]; UNC Office of Tech Dev MTA; Shaun Ryan
Cc: Morabito, Kaitlyn (NIH/VRC) [E]; Sunny Himansu (b)(6) Baric, Ralph
Subject: RE: NIAID/UNC/Moderna MTA
Attachments: NIAID - UNC - Moderna MTA (12.10.19 draft) (00034264xD7FD0)_final
clean_PE_NIAID.pdf

Hi Carmen,

Please find the partially executed MTA attached for signature at UNC.

Thanks,
Amy

From: Stein, Judy (NIH/VRC) [C] (b)(6)
Sent: Wednesday, December 11, 2019 4:39 PM
To: UNC Office of Tech Dev MTA <mta@unc.edu>; Shaun Ryan (b)(6)@modernatx.com>
Cc: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6) Sunny Himansu (b)(6)@modernatx.com> (b)(6) (b)(6)@modernatx.com>; Baric, Ralph (b)(6)
Subject: RE: NIAID/UNC/Moderna MTA

Hi Carmen,
Amy Petrik, our tech transfer specialist, can finalize and sign the agreement first.
Thanks very much.
Judy

From: UNC Office of Tech Dev MTA <mta@unc.edu>
Sent: Wednesday, December 11, 2019 4:35 PM
To: Shaun Ryan (b)(6)@modernatx.com>
Cc: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Stein, Judy (NIH/VRC) [C] (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6) Sunny Himansu (b)(6)@modernatx.com>; (b)(6)@modernatx.com>; Baric, Ralph (b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>
Subject: RE: NIAID/UNC/Moderna MTA

Thanks, Shaun!

Judy – let me know if you would prefer to initiate signature or if you would like us to. I'm happy to do either!

Best,
Carmen

Carmen Melvin

Licensing Manager | Office of Technology Commercialization
The University of North Carolina at Chapel Hill | 109 Church Street | Chapel Hill, NC 27516
(b)(6) | 919-966-3929 (office) | (b)(6) (direct)
CDAs: otc_cda@unc.edu | MTAs: mta@unc.edu | Tangible Property Program: researchtools@unc.edu

From: Shaun Ryan (b)(6)@modernatx.com>
Sent: Wednesday, December 11, 2019 12:56 PM
To: UNC Office of Tech Dev MTA <mta@unc.edu>
Cc: (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6)
Sunny Himansu (b)(6)@modernatx.com>; (b)(6)
(b)(6)@modernatx.com>; Baric, Ralph S (b)(6)
Subject: RE: NIAID/UNC/Moderna MTA

Thank you Carmen, these changes are acceptable to Moderna.

We defer to UNC and NIAID regarding the preferred method of execution – please let us know how you would like to proceed.

Best,

Shaun

Shaun Ryan
SVP & Deputy General Counsel | Moderna (b)(6)

From: UNC Office of Tech Dev MTA [<mailto:mta@unc.edu>]
Sent: Wednesday, December 11, 2019 12:52 PM
To: Shaun Ryan (b)(6)@modernatx.com>
Cc: (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6)
Sunny Himansu (b)(6)@modernatx.com>; (b)(6)
(b)(6)@modernatx.com>; Baric, Ralph S (b)(6) UNC Office of Tech Dev
MTA <mta@unc.edu>
Subject: RE: NIAID/UNC/Moderna MTA

Hi Shaun,

Moderna's edits are acceptable to UNC with a few revisions to Section 4 (see attached). Please let us know if there are any questions or concerns with this change. I'm happy to discuss over the phone if helpful.

Best,
Carmen

Carmen Melvin
Licensing Manager | Office of Technology Commercialization
The University of North Carolina at Chapel Hill | 109 Church Street | Chapel Hill, NC 27516

(b)(6) | 919-966-3929 (office) | (b)(6) direct)
CDAs: otc_cda@unc.edu | MTAs: mta@unc.edu | Tangible Property Program: researchtools@unc.edu

From: Shaun Ryan (b)(6)@modernatx.com>
Sent: Tuesday, December 10, 2019 3:48 PM
To: UNC Office of Tech Dev MTA <mta@unc.edu>; Baric, Ralph S (b)(6) Baric, Ralph S (b)(6)
Cc: (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6)
Sunny Himansu (b)(6)@modernatx.com> (b)(6)
(b)(6)@modernatx.com>
Subject: NIAID/UNC/Moderna MTA

All,

Attached please a handful of proposed revisions to the NIAID/UNC/Moderna MTA. The attached draft is acceptable to both NIAID and Moderna. Would UNC please let us know if the attached version is acceptable, or if it would be useful to have a brief call to discuss?

Best regards,

Shaun

Shaun Ryan

SVP & Deputy General Counsel | Moderna (b)(6)

From: (b)(6)
Sent: Friday, December 6, 2019 4:00 PM
To: Stein, Judy (NIH/VRC) [C] (b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>
Cc: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Sunny Himansu (b)(6)@modernatx.com>; Baric, Ralph (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6)
Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Thank you, Judy. I have forwarded to Moderna's legal group, who are still reviewing the initial version of the document.

Best regards,

(b)(6)

From: Stein, Judy (NIH/VRC) [C] (b)(6)
Sent: Friday, December 6, 2019 3:32 PM
To: UNC Office of Tech Dev MTA <mta@unc.edu> (b)(6)@modernatx.com>
Cc: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Sunny Himansu (b)(6)@modernatx.com>; Baric, Ralph (b)(6) Petrik, Amy (NIH/NIAID) [E] (b)(6)

(b)(6)

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Thanks Carmen.

(b)(6) Would you be able to review this version and let us know if it is acceptable.
Judy

From: UNC Office of Tech Dev MTA <mta@unc.edu>

Sent: Friday, December 6, 2019 3:26 PM

To: Stein, Judy (NIH/VRC) [C] (b)(6) Sophia Zendzian

(b)(6)@modernatx.com>

Cc: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Sunny Himansu

(b)(6)@modernatx.com>; Baric, Ralph (b)(6) Petrik, Amy (NIH/NIAID) [E]

(b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Please see attached. UNC has only a few edits to the provided draft. Don't hesitate to let us know if there are any questions or comments.

We are waiting on some additional input from our investigator, but do not anticipate any further changes.

Best,
Carmen

Carmen Melvin

Licensing Manager | Office of Technology Commercialization

The University of North Carolina at Chapel Hill | 109 Church Street | Chapel Hill, NC 27516

(b)(6) | 919-966-3929 (office) | (b)(6) (direct)

CDAs: otc_cda@unc.edu | MTAs: mta@unc.edu | Tangible Property Program: researchtools@unc.edu

From: UNC Office of Tech Dev MTA <mta@unc.edu>

Sent: Friday, December 06, 2019 10:04 AM

To: Stein, Judy (NIH/VRC) [C] (b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>;

Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) Sophia Zendzian

(b)(6)@modernatx.com>

Cc: Sunny Himansu (b)(6)@modernatx.com>; Baric, Ralph S (b)(6) Petrik,

Amy (NIH/NIAID) [E] (b)(6)

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Happy to, Judy. I will review the draft today. I can already say that the jurisdiction language is acceptable to UNC.

Best,
Carmen

Carmen Melvin

Licensing Manager | Office of Technology Commercialization
The University of North Carolina at Chapel Hill | 109 Church Street | Chapel Hill, NC 27516
(b)(6) | 919-966-3929 (office) | (b)(6) (direct)
CDAs: otc_cda@unc.edu | MTAs: mta@unc.edu | Tangible Property Program: researchtools@unc.edu

From: Stein, Judy (NIH/VRC) [C] (b)(6)
Sent: Thursday, December 05, 2019 2:13 PM
To: UNC Office of Tech Dev MTA <mta@unc.edu>; Morabito, Kaitlyn (NIH/VRC) [E]
(b)(6) (b)(6) @modernatx.com>
Cc: Sunny Himansu (b)(6) @modernatx.com>; Baric, Ralph S (b)(6) Petrik,
Amy (NIH/NIAID) [E] (b)(6)
Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Hi everyone,
I have attached the original agreement. I believe that Moderna was inserting the shipping address but as of now, there have been no changes to the terms.
Carmen, perhaps you can insert your suggested edits and circulate, although the jurisdiction language could be consistent with other NIAID agreements, we would appreciate it.

Thanks,
Judy
From: UNC Office of Tech Dev MTA <mta@unc.edu>
Sent: Thursday, December 5, 2019 2:04 PM
To: Stein, Judy (NIH/VRC) [C] (b)(6) Morabito, Kaitlyn (NIH/VRC) [E]
(b)(6) (b)(6) @modernatx.com>
Cc: Sunny Himansu (b)(6) @modernatx.com>; Baric, Ralph (b)(6) UNC
Office of Tech Dev MTA <mta@unc.edu>; Petrik, Amy (NIH/NIAID) [E] (b)(6)
Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Hi all,

To my knowledge, my office has not received a draft MTA for this transfer. I am happy to review one once it is received. We may need to add/edits terms due to our status as a state institution.

Best,
Carmen

Carmen Melvin

Licensing Manager | Office of Technology Commercialization
The University of North Carolina at Chapel Hill | 109 Church Street | Chapel Hill, NC 27516
(b)(6) | 919-966-3929 (office) | (b)(6) (direct)
CDAs: otc_cda@unc.edu | MTAs: mta@unc.edu | Tangible Property Program: researchtools@unc.edu

From: Stein, Judy (NIH/VRC) [C] (b)(6)
Sent: Thursday, December 05, 2019 9:27 AM
To: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6) (b)(6)

(b)(6)@modernatx.com>

Cc: Sunny Himansu (b)(6)@modernatx.com>; Baric, Ralph S (b)(6) UNC
Office of Tech Dev MTA <mta@unc.edu>; Petrik, Amy (NIH/NIAID) [E] (b)(6)
Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Hi everyone,

We would like to complete this MTA within the next 2 weeks if possible.

(b)(6) and Ralph,

Can you please let me know if the legal reviews are completed and if so, are there any requested changes. Once we are all in agreement, NIAID can sign first and then circulate to the others.

Thanks very much.

Judy

Judy Stein, MBA, MSPH
Strategic Planning and Development
Contractor to Vaccine Research Center, NIAID, NIH
Tel: (b)(6)

From: Morabito, Kaitlyn (NIH/VRC) [E] (b)(6)

Sent: Wednesday, October 30, 2019 9:32 AM

To: Stein, Judy (NIH/VRC) [C] (b)(6) (b)(6)

(b)(6)@modernatx.com>

Cc: Sunny Himansu (b)(6)@modernatx.com>; Baric, Ralph (b)(6) UNC
Office of Tech Dev MTA <mta@unc.edu>

Subject: Re: MERS S mRNA Vaccine for Challenge Studies

Hi All,

This is the shipping address that we have used for sending reagents to UNC.

Sarah Leist/Ralph Baric
UNC-CH
135 Dauer Drive
3105 MHRC
Chapel Hill, NC 27599
Phone# (b)(6)

Thanks,
Kaitlyn

From: Judy Stein (b)(6)
Date: Sunday, October 27, 2019 at 1:13 PM
To: (b)(6)@modernatx.com>

Cc: Sunny Himansu (b)(6)@modernatx.com>, "Morabito, Kaitlyn (NIH/VRC) [E]" (b)(6) Ralph Baric (b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Hi Ralph,

Would you be able to provide the shipping address for the material. Moderna is reviewing a MTA that lists VRC and Moderna as the providers and UNC as the recipient.

Once they review and comment, we will send it to you for review.

Thanks,

Judy

From: (b)(6)@modernatx.com>

Sent: Friday, October 25, 2019 3:04 PM

To: Stein, Judy (NIH/VRC) [C] (b)(6)

Cc: Sunny Himansu (b)(6)@modernatx.com>; Morabito, Kaitlyn (NIH/VRC) [E]

(b)(6) Baric, Ralph (b)(6) UNC Office of Tech Dev MTA <mta@unc.edu>

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Thank you, Judy. Would you, or perhaps someone on the UNC side, happen to know the receiving address?

Thank you,

(b)(6) Moderna
(b)(6)@modernatx.com | modernatx.com
mobile (b)(6) | fax (b)(6)

From: Stein, Judy (NIH/VRC) [C] (b)(6)

Sent: Tuesday, October 15, 2019 9:48 AM

To: (b)(6)@modernatx.com>

Cc: Sunny Himansu (b)(6)@modernatx.com>; Morabito, Kaitlyn (NIH/VRC) [E]

(b)(6)

Subject: RE: MERS S mRNA Vaccine for Challenge Studies

Hi (b)(6)

Can you please look at this attached draft MTA and let me know if you have comments. Once Moderna and NIAID agree, I will send this to UNC.

Thanks,

Judy

Judy Stein, MBA, MSPH
Senior Manager

